Market Trends of Europe Renal Denervation Devices Industry
The Ultrasound-based Segment is Expected to Witness Significant Growth Over the Forecast Period
The ultrasound-based renal denervation devices use ultrasound to ablate nerves in the wall of the renal arteries in minimally invasive procedures. It disrupts the transmission of nerve impulses to and from the kidney and lowers blood pressure.
The ultrasound-based renal denervation devices are expected to grow in the market, owing to the high prevalence of hypertension, stress, and the benefits of ultrasound-based renal denervation for managing the disease. Several research studies have highlighted the efficacy of ultrasound-based renal denervation devices for managing hypertension, which is anticipated to attract more patient demand and support the market players to offer more ultrasound-based renal denervation devices. These factors are expected to boost the growth of the segment. For instance, a study published in the EuroIntervention in 2021 demonstrated the proven efficacy of lowering blood pressure by ultrasound-based renal denervation in patients.
Further, in a study published in the Journal Lancet in May 2021, ultrasound renal denervation decreased the blood pressure within two months of the procedure of hypertensive patients resistant to triple combination pills. The triple combination pill consisted of anti-hypertensive drugs, including a calcium channel blocker, a thiazide diuretic, and an angiotensin receptor blocker. These studies demonstrated ultrasound-based renal denervation for managing anti-hypertensive drugs resistant patients. Thus, ultrasound renal denervation can be a highly effective treatment for resistant anti-hypertensive drugs.
Additionally, several factors are associated with hypertension in European countries which is believed to boost segment growth. For instance, stress is one of the key factors for hypertension in the young population. The Labor Force Survey conducted in November 2022 in the United Kingdom indicated that around 914 per 1,000 young individuals were having work-related stress in the country which is leading to the conditions, such as hypertension.
Therefore, the ultrasound-based segment is expected to witness a significant growth over the forecast period due to the rising prevalence of hypertension and the effectiveness of ultrasound-based therapies in managing the same.
Germany is Expected to Dominate the Europe Renal Denervation Devices Market
Germany is expected to dominate the market owing to factors such as the high prevalence of hypertension, highly advanced medical and research infrastructure, and key developments by the market players in the country.
The country has a significant hypertension burden associated with the serious medical issue of high blood pressure, elevated risk of stroke, kidney disease, and heart failure. These issues are expected to increase the need for renal denervation procedures, which is likely to boost the demand for renal denervation devices and boost the segment's growth. For instance, a study published in the journal Original Cardiovascular in 2022 mentioned that Germany recorded 161,261 heart surgeries in 2021. Such a high volume of heart surgeries reflects the severity of the cardiac issues which are contributed by hypertension, which renal denervation procedures can control. Thus, such a high burden of cardiac disease is expected to drive the segment's growth in the coming years.
Furthermore, the key developments in Germany are also expected to boost the market in the country, which is likely to increase the market penetration in the country. For instance, in October 2021, ReCor Medical Inc. launched the ultrasound renal denervation system in Europe, which is being used to treat uncontrolled hypertension in Germany.
Therefore, owing to the factors above, including the significant burden of cardiac diseases driven by hypertension and the recent developments by the market players, the growth of the market studied is anticipated in Germany.
